Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56). (30th November 2019)

• Record Type: Journal Article
• Authors: Tiraboschi, Juan; Imaz, Arkaitz; Khoo, Saye; Niubo, Jordi; Prieto, Paula; Saumoy, Maria; Penchala, Sujan Dilly; Garcia, Benito; Padilla, Cristina; Videla, Sebastian; Podzamczer, Daniel
• Is Part Of: Journal of infectious diseases. Volume 221:Number 9(2020)
• Page Start: 1425
• Page End: 1428
• Publication Date: 2019-11-30
• Subjects: bictegravir -- CNS -- concentrations -- unbound; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiz624
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: We determined total and unbound concentrations of bictegravir (BIC) in cerebrospinal fluid (CSF) in 15 asymptomatic, virologically suppressed patients. The median plasma and CSF total BIC concentrations were 1837.1 ng/mL (interquartile range [IQR], 1237.2–2586.7) and 6.9 (IQR, 4.8–10.9), respectively. Median unbound BIC concentration was 2.48 ng/mL (IQR, 1.6–3.7). Total and unbound BIC CSF concentrations were above the half-maximal effective concentration value in all patients, and all subjects had human immunodeficiency virus viral suppression in plasma and CSF. Bictegravir may contribute to inhibit viral replication in this compartment. Abstract : Total and unbound bictegravir concentrations in cerebrospinal fluid were above the EC50 value in all 15 patients. All subjects had HIV viral suppression in plasma and CSF. Bictegravir may contribute to inhibit viral replication in this compartment.